Therapeutic Focus

Leadership in Ubiquitin Drug Discovery: From PROTACs to Molecular Glues

Progenra’s UbiProTM is a robust drug discovery platform derived from the ubiquitin-proteasome system (UPS), a major regulator of cellular functions. The UbiProTM platform enables us to discover and rapidly characterize unique ligands, molecular glues, inhibitors, and activators of E3 ubiquitin ligases and Deubiquitinases (DUBs). These small molecule UPS modulators are being employed to modulate stability and functions of disease-relevant target proteins.

Progenra has discovered Molecular Glue degraders for multiple therapeutic targets including KRAS, IRAK4 and aggregated Tau. 

Progenra has utilized its novel E3 ligands to generate PROTACs that are extremely potent in selectively degrading therapeutic targets such as receptor tyrosine kinases (RTKs) and KRAS. Progenra continues to develop first in class breakthrough drug candidates with in vivo proof of concept.

We are continually incorporating innovative therapeutic modalities including the most recent Protein Rescue Targeting Chimeras (PRESTACs). The heterobifunctional PRESTACs enable stabilization of disease relevant target proteins by reversing the ubiquitin-mediated degradation process.

Our therapeutic focus is the discovery and development of clinical candidates in cancer, neurodegenerative disease cardiovascular disease and inflammatory disease.